Compare LNSR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNSR | ELDN |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 120.8M |
| IPO Year | N/A | N/A |
| Metric | LNSR | ELDN |
|---|---|---|
| Price | $10.27 | $1.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $15.00 | $11.00 |
| AVG Volume (30 Days) | 75.6K | ★ 4.0M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,141,000.00 | N/A |
| Revenue This Year | $30.80 | N/A |
| Revenue Next Year | $33.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.02 | N/A |
| 52 Week Low | $7.13 | $1.35 |
| 52 Week High | $17.31 | $5.08 |
| Indicator | LNSR | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 31.96 |
| Support Level | $9.56 | $1.54 |
| Resistance Level | $10.48 | $1.68 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 74.31 | 22.41 |
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.